Post on 04-Jun-2018
8/13/2019 DM Sementara
1/9
General Objectives of Diabetes Management:
To relieve symptoms
To correct associated health problems and to reduce morbidity, mortality andeconomic costs of diabetes
To prevent as much as possible acute and long-term complications and toprovide timely intervention
To improve the quality of life and productivity of the individual ith diabetes
A. Diet
Diet is a basic part of management in every case! Treatment cannot be effective
unless adequate attention is given to ensuring appropriate nutritionDietary treatment should aim at:
a! ensuring eight control
b! providing nutritional requirements
c! allo ing good glycaemic control ith blood glucose levels as close tonormal as possible
d! correcting any associated blood lipid abnormalities
The following principles are recommended as dietary guidelines for peoplewith diabetes:
Dietary fat should provide 25-35% of total intake of calories but saturatedfat intake should not e"ceed 10% of total energy! #holesterol consumptionshould be restricted and limited to $%% mg or less daily!
&rotein inta'e can range bet een 10-15% total energy (%!)-* g+'g ofdesirable body eight ! equirements increase for children and duringpregnancy! &rotein should be derived from both animal and vegetablesources!
#arbohydrates provide 50-60% of total caloric content of the diet.#arbohydrates should be comple" and high in fibre!
."cessive salt inta'e is to be avoided! /t should be particularly restricted inpeople ith hypertension and those ith nephropathy!
!ercise
8/13/2019 DM Sementara
2/9
&hysical activity promotes eight reduction and improves insulin sensitivity,thus lo ering blood glucose levels!
Together ith dietary treatment, a programme of regular physical activityand e"ercise should be considered for each person! 0uch a programme must
be tailored to the individual1s health status and fitness!&eople should, ho ever, be educated about the potential ris' ofhypoglycaemia and ho to avoid it!
Mechanism of 2ction
0ulfonylureas interact ith receptors on pancreatic b-cells to bloc' 2T&-sensitive potassium channels
This, in turn, leads to opening of calcium channels
3hich leads to the production of insulin
0econd Generation 0ulfonylureas
"lipi#ide
$!idi#ed to inacti e metabolites
&alf-life - ' to ( hours
)otency - &igh
*'.5 to (0 mg+d,
."tended-release preparation- glipi4ide G/T0
5 Glipi4ide gastrointestinal therapeutic system
5 Does not induce eight gain
#linical 6ses of 0ulfonylureas
7ypoglycemic agents for treatment of Type 8 diabetes mellitus
2ct by increasing endogenous insulin secretion 9 not indicated for Type * Most effective hen cell function has not been severely compromised
/ncreased insulin secretion favors lipogenesis
Most appropriate in non- or mildly obese
6p to *;% < of ideal body eight
8/13/2019 DM Sementara
3/9
#hoice of 0ulfonylurea
onsider:
Duration of action, potency, metabolism, side effects
/n presence of renal dysfunction:
- Dual routes of elimination
Glyburide or glimepiride
- Metaboli4ed to inactive metabolites
Glipi4ide
0econd generation 06s bind nonionically to plasma albumin and have fe er druginteractions than earlier 06s, hich bind albumin ionically and compete ith other
drugs for binding sites
=iguanides : improves insulin1s ability to move glucose into cells (esp! muscle
- mechanism improves insulin sensitivity by increasing peripheral glucose upta'e
and utili4ation!
- >hou et al (8%%* sho ed that metformin stimulates the hepatic en4yme 2M&-
activated protein 'inase- Metformin as first described in the scientific literature in *?@A (6nger et al !
- /t as first mar'eted in Brance in *?A? but did not receive BD2 approval for Type
8 diabetes until *??C!
etformin is a widely used monotherapy/ and also used in combinationwith the sulfonylureas in treatment of type ' diabetes
=iguanides
Birst Generation- &henformin
&henethylbiguanide
2dverse .ffects
8/13/2019 DM Sementara
4/9
actic acidosis
is' of cardio-
vascular disorder
#urrently in use in the 6!0!
arely produces lactic acidosis e"cept under predisposing conditions
echanism of action: antihyperglycemic
orrect ele ated hepatic glucose output
nhibit gluconeogenesis
nhibit glucose- -phosphatase acti ity glycogen sparing insulin resistance
ediated by acti ation of 52A )-acti ated protein 3inase*A )4, in hepatocytes and muscle
Do not increase insulin secretion
ot hypoglycemic/ e en at high doses
Do not produce hypoglycemia
6econdary beneficial effects on lipids
7educed triglycerides
7educed total cholesterol
7educed 8D8
ncreased &D8
nsulin le els unchanged or reduced
9eight loss/ some reduction of blood pressure
Appropriate for obese Type ' diabetics
8/13/2019 DM Sementara
5/9
!creted unchanged in the urine
&alf-life - appro!imately ' hours
Does not bind to plasma proteins
6hould not be used with renal or hepatic dysfunction
Also appro ed for pre ention of Type ' diabetes in high ris3indi iduals
se also for polycystic o ary syndrome: insulin resistance witho arian hyperandrogenism
Thia4olidinediones (T>D1s : ma'e cells more sensitive to insulin (esp! fatty cells
binds to and activates the gamma isoform of the pero"isome proliferator-activated
receptor (&&2 E !
&&2 E is a member of the steroid hormone nuclear receptor superfamily, and isfound in adipose tissue, cardiac and s'eletal muscle, liver and placenta
upon activation of this nuclear receptor by a ligand such as a T>D, &&2 EFligandcomple" binds to a specific region of D 2 and thereby regulates the transcription ofmany genes involved in glucose and fatty acid metabolism!
Thia4olidinediones: osiglita4one
;ioa ailability of oral dose is
8/13/2019 DM Sementara
6/9
8/13/2019 DM Sementara
7/9
.ffective regardless of age, genetic factors, body eight, duration or severityof disease
2carbose
Metaboli4ed ithin the digestive tract by en4ymes and intestinal bacteria
o systemic bioavailability
I 8 < is absorbed as intact molecule
2dverse effects: Gastrointestinal disturbances
Blatulence
ausea
Diarrhea
6se gradual dose titration
#ontraindicated for inflammatory and obstructive bo el disease,colonic ulcers
Meglitinides : 0timulate more insulin production J dependant upon level of glucosepresent
epaglinide and ateglinide
Mechanism of action:
t decrease 2T&-sensitive K L conductance
t 2dditional high affinity binding site identified in mouse -cells forrepaglinide
2ction is glucose dependent
7igh potency .licited insulin release is rapid and brief
t Ta'en ith meals for postprandial hyperglycemia
t educed ris' of long-lasting hypoglycaemia
8/13/2019 DM Sementara
8/9
Dipeptidyl-&eptidase C /nhibitors
2gent in #lass: 0itagliptin, 0a"agliptin
Mechanism of action:
slo s the inactivation of incretin hormones (glucagon-li'e peptide *and glucose-dependent insulinotropic polypeptide
/ncreases glucose-stimulated insulin secretion
#auses glucose-stimulated glucagon suppression
primarily lo ers postprandial glucose levels but has also been sho nto reduce fasting plasma glucose
D&&-/ inhibitors e"hibit both short term and long term actions of G &-*
2ugment glucose induced insulin secretion
/nhibit glucagon secretion
0lo gastric emptying
/ncrease insulin biosynthesis
&romote beta cell differentiation
Oral 2gent Monotherapy
/f glycaemic control is not achieved (7b2*c N ;!@< and+orJ B&G N A!% mmol+orJ &G N**!%mmol+ ith lifestyle modification ithin * F$ months, O 22 T/-D/2=.T/# 2G. T should be initiated!
/n the presence of mar'ed hyperglycaemia in ne ly diagnosed symptomatictype 8 diabetes (7b2*c N )D!
8/13/2019 DM Sementara
9/9
on-obese type 8 patients, consider the use of metformin or insulinsecretagogues
Metformin is the drug of choice in over eight+obese patients! T>Ds andacarbose are acceptable alternatives in those ho are intolerant to
metformin!/f monotherapy fails, a combination of T>Ds, acarbose and metformin isrecommended! /f targets are still not achieved, insulin secretagogues may beadded
#ombination Oral 2gents
#ombination oral agents is indicated in:
e ly diagnosed symptomatic patients ith 7b2*c N*%
&atients ho are not reaching targets after $ months on monotherapy